U.S. Transdermal Drug Delivery System Market Analysis Report By Technology (Active, Passive), By Application (Hormone, Cardiovascular, Neurodegenerative, CNS, Pain Management), And Segment Forecasts, 2019 - 2026

Published: Nov, 2019 | Pages: 75 | Publisher: Grand View Research
Industry: Medical Devices | Report Format: Electronic (PDF)

The U.S. transdermal drug delivery system market size is anticipated to reach USD 30.5 billion by 2026, according to a new report by Grand View Research, Inc., registering a 9.5% CAGR over the forecast period. This can be attributed to increasing demand for pain-free drug delivery and self-administration of medication. In addition, technological advancements are expected to fuel market growth. For instance, smart patches are estimated to enable auto-injection of medication and monitoring of body parameters, along with the transmission of patient-generated data, thus improving timing and accuracy of drug administration.

Transdermal patches are increasingly becoming popular amongst patient population. This can be attributed to various benefits of patches over oral administration. For instance, a patch has better bioavailability and administration from a patch can be easily terminated by patch removal. Furthermore, the patch is non-invasive, painless, and convenient to use, thus increasing patient compliance.

On the down side, high costs associated with the development of novel drug-patch combinations and high product recalls are anticipated to limit market growth. In 2019, Alvogen recalled its fentanyl patches due to a labeling error, while in 2018, Teva Pharmaceuticals recalled millions of its fentanyl patches due to drug degradation issues. Such product recalls are anticipated to increase the stringency of market regulations and pose a barrier for new entrants.

Mergers and acquisitions, product launches, and strategic collaborations are some of the key sustainable strategies undertaken by market players. For instance, in 2018, Mylan announced the availability of its Rivastigmine Transdermal System (generic version of Exelon Patch), thus expanding its product portfolio.

Further key findings from the study suggest:

• By technology, the passive segment dominated the market in 2018, fueled by easy development process of these patches. The reservoir patch sub-segment is anticipated to witness lucrative growth over the forecast period thanks to the relatively greater control of drug delivery rate it offers

• Based on application, pain management led the market in 2018 owing to availability of several opioids and nonopioids analgesics patches in the market. The hormone segment is likely to exhibit strong growth driven by increasing prevalence of hormone imbalance

• Some of the key companies in the market are Corium International; TherapeuticsMD; Johnson & Johnson; Boehringer Ingelheim GmbH; Novartis AG; Mylan Pharmaceuticals, Inc.; The Tapemark Company; 3M; and AdhexPharma.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Summary, 2018
Chapter 3. U.S. Transdermal Drug Delivery System Market Variables, Trends & Scope
3.1. Market Segmentation & Scope
3.2. Market Driver Analysis
3.3. Market Restraint Analysis
3.4. SWOT Analysis, By Factor
3.4.1. Political
3.4.2. Economic
3.4.3. Technological
3.5. Industry Analysis - Porter's
Chapter 4. U.S. Transdermal Drug Delivery System Market: Technology Estimates & Trend Analysis
4.1. Technology Movement Analysis & Market Share, 2018 & 2026
4.2. Market Size & Forecasts and Trend Analysis, 2015 to 2026 for the following Technology:
4.2.1. Active
4.2.2. Passive
4.2.2.1. Matrix
4.2.2.2. Reservoir
Chapter 5. U.S. Transdermal Drug Delivery System Market: Application Estimates & Trend Analysis
5.1. Application Movement Analysis & Market Share, 2018 & 2026
5.2. Market Size & Forecasts and Trend Analysis, 2015 to 2026 for the following Application
5.2.1. CNS
5.2.1.1. Nausea & Vomiting
5.2.1.2. ADHD
5.2.2. Pain Management
5.2.3. Hormone
5.2.3.1. Men
5.2.3.2. Women
5.2.4. Addiction Therapies
5.2.5. Cardiology
5.2.5.1. Hypertension
5.2.5.2. Angina
5.2.6. Neurodegenerative
5.2.6.1. Parkinson's Disease
5.2.6.2. Alzheimer's Disease
5.2.7. Urology
Chapter 6. Competitive Landscape
6.1. Company Profiles
6.2. Contract Development And Manufacturing Organization (CDMO)
6.2.1. AdhexPharma
6.2.1.1. Company overview
6.2.1.2. Product benchmarking
6.2.1.3. Strategic initiatives
6.2.2. The Tapemark Company
6.2.2.1. Company overview
6.2.2.2. Product benchmarking
6.2.2.3. Strategic initiatives
6.2.3. Tesa-Labtec
6.2.3.1. Company overview
6.2.3.2. Product benchmarking
6.2.3.3. Strategic initiatives
6.2.4. 3M
6.2.4.1. Company overview
6.2.4.2. Product benchmarking
6.2.4.3. Strategic initiatives
6.3. Commercial-stage Pharmaceutical Companies
6.3.1. Novartis AG
6.3.1.1. Company overview
6.3.1.2. Product benchmarking
6.3.1.3. Strategic initiatives
6.3.2. Johnson & Johnson (Janssen Pharmaceuticals)
6.3.2.1. Company overview
6.3.2.2. Product benchmarking
6.3.2.3. Strategic initiatives
6.3.3. Mylan Pharmaceuticals, Inc.
6.3.3.1. Company overview
6.3.3.2. Product benchmarking
6.3.3.3. Strategic initiatives
6.3.4. Boehringer Ingelheim GmbH
6.3.4.1. Company overview
6.3.4.2. Product benchmarking
6.3.4.3. Strategic initiatives
6.3.5. Watson Pharmaceuticals, Inc.
6.3.5.1. Company overview
6.3.5.2. Product benchmarking
6.3.5.3. Strategic initiatives
6.3.6. Noven Pharmaceuticals, Inc.
6.3.6.1. Company overview
6.3.6.2. Product benchmarking
6.3.6.3. Strategic initiatives
6.3.7. Teva Pharmaceutical Inc.
6.3.7.1. Company overview
6.3.7.2. Product benchmarking
6.3.7.3. Strategic initiatives
6.3.8. Bayer Healthcare Pharmaceuticals Inc.
6.3.8.1. Company overview
6.3.8.2. Product benchmarking
6.3.8.3. Strategic initiatives
6.3.9. Amneal Pharmaceuticals LLC
6.3.9.1. Company overview
6.3.9.2. Product benchmarking
6.3.9.3. Strategic initiatives
6.3.10. LTS Lohmann Therapie-Systeme AG
6.3.10.1. Company overview
6.3.10.2. Product benchmarking
6.3.10.3. Strategic initiatives
6.4. Clinical-stage Pharmaceutical Companies
6.4.1. Taho Pharmaceuticals Ltd
6.4.1.1. Company overview
6.4.1.2. Product benchmarking
6.4.1.3. Strategic initiatives
6.4.2. Corsair Pharma/United Therapeutics Corporation
6.4.2.1. Company overview
6.4.2.2. Product benchmarking
6.4.2.3. Strategic initiatives
6.4.3. TherapeuticsMD
6.4.3.1. Company overview
6.4.3.2. Product benchmarking
6.4.3.3. Strategic initiatives
6.4.4. Corium International
6.4.4.1. Company overview
6.4.4.2. Product benchmarking
6.4.4.3. Strategic initiatives